2. Academic Validation
  3. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer

  • Oncologist. 2017 Apr;22(4):375-e30. doi: 10.1634/theoncologist.2016-0133.
Rocío García-Carbonero 1,  Eric van Cutsem 2,  Fernando Rivera 3,  Jacek Jassem 4,  Ira Gore Jr 5,  Niall Tebbutt 6,  Fadi Braiteh 7,  Guillem Argiles 8,  Zev A Wainberg 9,  Roel Funke,  Maria Anderson,  Bruce McCall,  Mark Stroh,  Eric Wakshull,  Priti Hegde,  Weilan Ye,  Daniel Chen,  Ilsung Chang,  Ina Rhee,  Herbert Hurwitz 10
Affiliations

Affiliations

  • 1 Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.
  • 2 UZ Leuven Oncologie, Leuven, Belgium.
  • 3 Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • 4 Medical University of Gdansk, Gdansk, Poland.
  • 5 Birmingham Hematology Oncology Associates, LLC, Birmingham, Alabama, USA.
  • 6 Austin Health, Medical Oncology, Heidelberg, Victoria, Australia.
  • 7 Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA.
  • 8 Hospital Universitario Vall d'Hebron, Departamento de Oncología, Barcelona, Spain.
  • 9 University of California, Los Angeles, Los Angeles, California, USA.
  • 10 Duke Clinical Research Institute, Durham, North Carolina, USA [email protected].
PMID: 28275117 DOI: 10.1634/theoncologist.2016-0133
Figures
Products